| Oregon Health and Science University Patent applications |
| Patent application number | Title | Published |
|---|
| 20150196786 | PORTABLE FIRE DRILL TRAINING APPARATUS - Portable fire drill training apparatuses which mimic an actual building install of a fire alarm system for training in localized areas are disclosed. In one example approach, a portable fire drill training apparatus is described which lacks any heat, smoke, or fire detectors and comprises an enclosure, a fire alarm notification appliance mounted on the enclosure, and a manual fire alarm activation device with an actuation element, where the manual fire alarm activation device is mounted on the enclosure and is configured to activate the fire alarm notification appliance in response to a user engaging the actuation element. | 07-16-2015 |
| 20150132744 | METHODS OF DETECTING CELLS LATENTLY INFECTED WITH HIV - Disclosed are methods of detecting and isolating CD4 | 05-14-2015 |
| 20150118193 | IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOF - Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described. | 04-30-2015 |
| 20150051140 | MODIFICATION OF FEEDING BEHAVIOR - Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering PYY or an agonist thereof and GLP-1 or an agonist thereof to the subject, simultaneously or sequentially, thereby decreasing the calorie intake of the subject. | 02-19-2015 |
| 20150027439 | ANESTHETIC VAPORIZER - Disclosed herein is an anesthetic vaporizer comprising a refrigeration system configured to cool a liquid anesthetic to less than 0° C. and to the anesthetic's temperature of minimal alveolar concentration. Further disclosed are methods of administering a liquid anesthetic comprising cooling the liquid anesthetic to less than 0° C. and to the anesthetic's temperature of minimal alveolar concentration. | 01-29-2015 |
| 20140302530 | CMV GLYCOPROTEINS AND RECOMBINANT VECTORS - This invention also relates to recombinant vectors expressing one or more of the human CMV (HCMV) glycoproteins US2, US3, US6 and US11 or corresponding functional rhesus CMV (RhCMV) homologues Rh182, Rh184, Rh185 or Rh189, methods of making them, uses for them, expression products from them, and uses for the expression products. This invention also relates to recombinant cytomegalovirus vectors vectors lacking one or more of the glycoproteins, methods of making them, uses for them, expression products from them, and uses for the expression products. | 10-09-2014 |
| 20140289882 | COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC MODIFICATION FOR REPAIRING CARTILAGE DAMAGE - The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), MSCs, fibroblasts, hematopoietic stem cells, endothelian stem cells, adipocytes, chondrocytes, osteoblasts, osteoclasts and endothelial cells) into chondrogenic cells without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof. | 09-25-2014 |
| 20140242115 | INACTIVATING PATHOGENS WITH OXIDIZING AGENTS FOR VACCINE PRODUCTION - The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions (medicaments) containing a pathogen inactivated by exposure to hydrogen peroxide. Methods for eliciting an immune response in a subject by administering vaccine compositions containing a hydrogen peroxide inactivated pathogen are also provided. | 08-28-2014 |
| 20140066980 | CLOSURE DEVICE - A closure device for closing a bodily passageway is provided. The device includes first and second frames and first and second crossbars. A sheet of biocompatible material is attached to one or more of the frames. The first crossbar extends across the first frame and has terminal crossbar ends connectively linked to separate sites on the first frame; the second crossbar is similarly linked to the second frame. The crossbars are attached to each other at a connection point, and they are each configured to bend away from the connection point when the closure device is deployed to close a bodily passageway. A method of making the closure device is provided, as well as a method for closing a bodily passageway using such a device. Further, a closure device assembly is provided, including a closure device, a delivery catheter housing, and a delivery release member. | 03-06-2014 |
| 20140018253 | GENE EXPRESSION PANEL FOR BREAST CANCER PROGNOSIS - The invention described in the application relates to a panel of gene expression markers for node-negative, ER-positive, HER2-negative breast cancer patients. The invention thus provides methods and compositions, e.g., kits and/or microarrays, for evaluating gene expression levels of the markers and methods of using such gene expression levels to evaluate the likelihood of relapse of a node-negative, ER-positive, HER2-negative breast cancer patient. Such information can be used in determining treatment options for patients. | 01-16-2014 |
| 20130157294 | Methods and Compositions for the Diagnosis of Cancer Susceptibilities and Defective DNA Repair Mechanisms and Treatment Thereof - Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway. | 06-20-2013 |
| 20130142823 | CMV GLYCOPROTEINS AND RECOMBINANT VECTORS - This invention also relates to recombinant vectors expressing one or more of the human CMV (HCMV) glycoproteins US2, US3, US6 and US11 or corresponding functional rhesus CMV (RhCMV) homologues Rh182, Rh184, Rh185 or Rh189, methods of making them, uses for them, expression products from them, and uses for the expression products. This invention also relates to recombinant cytomegalovirus vectors vectors lacking one or more of the glycoproteins, methods of making them, uses for them, expression products from them, and uses for the expression products. | 06-06-2013 |
| 20130004525 | INACTIVATING PATHOGENS WITH OXIDIZING AGENTS FOR VACCINE PRODUCTION - The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions (medicaments) containing a pathogen inactivated by exposure to hydrogen peroxide. Methods for eliciting an immune response in a subject by administering vaccine compositions containing a hydrogen peroxide inactivated pathogen are also provided. | 01-03-2013 |
| 20120174244 | PROFILING FRAGMENTS OF ELASTIC FIBERS AND MICROFIBRILS AS BIOMARKERS FOR DISEASE - The present invention makes use of immunoassays, such as sandwich ELISAs, to profile the circulating concentration of elastic fiber and microfibril fragments in samples from individuals with diseases associated with elastic fiber and/or microfibril degradation. Examples of such diseases include, Marfan's syndrome, aortic aneurysm, and scleroderma. Profiling the concentration of such fragments can be used to diagnose disease and monitor disease progression. | 07-05-2012 |
| 20110213278 | MOVEMENT MONITORING SYSTEM AND APPARATUS FOR OBJECTIVE ASSESSMENT OF MOVEMENT DISORDERS - Disclosed embodiments include a movement monitoring system and apparatus for objective assessment of movement disorders of a subject, comprising (a) one or more movement monitors, and (b) a computer-implemented analysis system comprising one or more protocols and associated data analysis methods to objectively quantify movement disorders based on movement data acquired by the movement monitors. According to one embodiment, the movement monitors are robust wireless synchronized movement monitors and the protocols include one or more tests for assessment of neural control of balance. | 09-01-2011 |
| 20110213277 | SYSTEM, METHOD, AND APPARATUS FOR OBJECTIVE ASSESSMENT OF MOTOR SIGNS AT THE EXTREMITIES - Disclosed embodiments include a system for objective assessment of motor signs at the extremities that comprises (a) a device for objective motor sign measurement, (b) a test protocol defining a prescribed repetitive activity, and (c) a signal processing and analysis system to generate one or more impairment metrics. According to a particular embodiment, the device for objective motor sign measurement is characterized by including means for producing a continuous measure of position of a limb or extremity during said prescribed repetitive activity during the entire movement. | 09-01-2011 |
| 20090209461 | MODIFICATION OF FEEDING BEHAVIOR - Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the calorie intake of the subject. | 08-20-2009 |
| 20090104163 | Immunomodulatory Properties of Multipotent Adult Progenitor Cells and Uses Thereof - Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described. | 04-23-2009 |
| 20090062844 | SPIDER PFO CLOSURE DEVICE - A device for occluding septal defects or other bodily passageways including PFOs, includes an occluding body formed from a plurality of flexible outwardly radiating occluding wires connected to one or more biocompatible sheet materials. The occluding wires are joined together at proximal wire ends. Linking members connectively link the occluding body to a flexible, substantially linear anchor formed from at least one tube, coil, or bar. The anchor is configured for placement on one side of bodily passageway, whereby the longitudinal axis of at least one anchor extends across a transverse cross-section of the bodily passageway, anchoring the occluding body in place against the other side of a bodily passageway to close, occlude, or fill at least a lumenal portion of a bodily passageway. The anchor may include one or more grasping member(s) integrally formed or connected to the tube, coil, or bar for releasable attachment to an anchor engaging member, such as a biopsy forceps. In a further aspect, a closure device assembly includes a delivery catheter housing a collapsibly disposed closure device linked to a biopsy forceps. The biopsy forceps may be positioned in a locking catheter, which is configured to prevent inadvertent release of the closure device when held in a compressed state inside the delivery catheter. By positioning the catheter near a bodily passageway, such as a PFO, and disengaging the anchor engaging member from the grasping member, the closure device may be released so as to facilitate stable closure of the bodily passageway. | 03-05-2009 |
| 20080318236 | Cell Free Screening Assay and Methods of Use - Methods are disclosed for identifying agents for the treatment of cancer and/or Fanconi anemia using | 12-25-2008 |
| 20080214609 | Development of new selective estrogen receptor modulators - The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions. | 09-04-2008 |
| 20080206231 | Compositions and Methods for Treating Disease - The present invention discloses for the first time that the insulin receptor (IR) is a target of Herstatin, which modulates IR and IR-mediated intracellular signaling. In preferred aspects, Herstatin binds at nM concentrations to cell-surface IR, up-regulates basal IR expression by several-fold, induces the accumulation of pro-IR, and stimulates insulin activation of the ERK pathway. Moreover, these changes in insulin signaling are accompanied by alterations in IGF-IR expression, IRS-2 levels, and the serine phosphorylation state of both IRS-1 and IRS-2. Preferred aspects provide novel therapeutic methods and pharmaceutical compositions for treatment of conditions associated with altered IR expression or IR-mediated signaling, including but not limited to insulin resistance syndrome, pre-diabetic conditions, metabolic syndrome, type 1 and type 2 diabetes, cardiac disease, diabetes-associated vascular disease, atherosclerosis, hypertension, diabetes-associated lipid metabolism disorders (dyslipidemia), obesity, critical illness, neurodegenerative disorders, and combinations thereof, and cancer. | 08-28-2008 |
